Jazz Pharmaceuticals plc
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Jazz Pharmaceuticals plc (NASDAQ: JAZZ), headquartered in Dublin, Ireland and founded in 2003, develops and commercializes innovative biopharmaceutical products for serious diseases with significant unmet needs, primarily in neuroscience and oncology; its core portfolio includes Xywav and Xyrem (sodium oxybate formulations) for cataplexy and excessive daytime sleepiness in narcolepsy, Epidiolex (cannabidiol oral solution) for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, Defitelio (defibrotide) for severe hepatic veno-occlusive disease post-hematopoietic stem-cell transplantation, Rylaze (asparaginase erwinia chrysanthemi recombinant) for acute lymphoblastic leukemia, Vyxeos (daunorubicin and cytarabine liposome injection) for therapy-related acute myeloid leukemia and newly diagnosed acute myeloid leukemia, Zepzelca (lurbinectedin) for metastatic small cell lung cancer, Modeyso (vosoritide) for achondroplasia in pediatric patients, and Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer; products are marketed in nearly 75 countries across North America, Europe, and select international markets including Australia, Israel, Japan, Canada, and parts of the Middle East and Latin America. Recent developments include FDA approval of Ziihera (zanidatamab-hrii) in November 2024 for biliary tract cancer with ongoing pursuits in HER2-positive breast cancer, a March 2025 definitive agreement to acquire Chimerix for approximately $935 million to bolster its pipeline, an August 2025 exclusive licensing agreement with Saniona for SAN2355 targeting epilepsy and neurological conditions where Jazz leads global development and commercialization, a February 2024 deal with Redx Pharma acquiring global rights to a KRAS inhibitor program for up to $880 million, and a October 2025 research collaboration with Iambic Therapeutics on AI-driven drug discovery. The company maintains manufacturing facilities in Ireland, England and Italy, with significant operations in Palo Alto, Philadelphia, Oxford and Cambridge.
Company News
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout
Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
JAZZ vs. TECH: Which Stock Is the Better Value Option?
Jazz Pharmaceuticals' Re-Rating Story Has Legs